buy silo wellness stock

Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol "SILFF"

Silo Wellness Inc. (" Silo Wellness " or the " Company ") (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, announces that its common shares are now trading on the OTCQB® Venture Market under the symbol "SILFF". The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international companies, and trading on the OTCQB will enhance the visibility and accessibility of Silo Wellness to U.S. investors. Silo Wellness' common shares will continue to trade on the Canadian Securities Exchange under the symbol "SILO".

"Silo Wellness is pleased to be joining the OTCQB and improving access to our American shareholders. Our team is focused on building and accelerating the growth of the Marley One line of functional mushrooms, our Jamaican and Oregon wellness retreats, the cultivation of psychedelic mushrooms and truffles in Jamaica, the development of our brick-and-mortar smart shop in Jamaica and the commercialization of our metered-dosing psilocybin nasal spray," said Douglas Gordon, Chief Executive Officer of Silo Wellness.

ABOUT Silo Wellness

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly traded company on the Canadian (CSE: SILO) and Frankfurt (FRA: CK70) exchanges and trading on the OTCQB® Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.marleyone.com .

For more information about Silo Wellness, please visit www.silowellness.com .

For further information, please contact:

Silo Wellness Media Relations:
hello@trailblaze.co

Silo Wellness Investor Relations:
(778) 383-6740
ir@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the trading of Silo Wellness' common shares on the OTCQB® Venture Market, the partnership with the Marley brand, the effects of Silo Wellness' products and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Born Defense

Born Defense Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Born Defense

Born Defense

Psychedelic Healing Right Now & Pharmaceutical Biotech

Psychedelic Healing Right Now & Pharmaceutical Biotech Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
"2023 year-end review" text overlaid on image of psychedelic mushrooms.

Psychedelics Market 2023 Year-End Review

The psychedelics industry is maturing after the investment boom of 2020 and 2021, and patient long-term investors looking for opportunities to diversify their portfolios have options when it comes to exposure. As clinical trials and research continue to demonstrate the potential benefits of... Keep Reading...
Glowing pyschedelic mushrooms.

How to Invest in Psychedelics

Market participants are wondering how to invest in psychedelics as the opportunity attached to these drugs grows.Promising research associated with psychedelic medicine shows the potential for these products to treat mental health issues and even addiction to opioids. “(Psychedelic)-assisted... Keep Reading...
A colorful brain illustrating brain on pyschedelics.

Psychedelics Stocks to Watch

The small-cap market has been invaded by a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space.In an effort to expand the capabilities of the medical field, companies are starting to... Keep Reading...
Albert Labs

Albert Labs Announces Expansion of Drug Discovery and a Promising Pipeline

Albert Labs International Corp. ([CSE: ABRT], the "Company" or "Albert Labs"), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs, is pleased to announce the expansion of its drug discovery pipeline, broadening the... Keep Reading...
Born Defense

Born Defense Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News